Ireland - English - HPRA (Health Products Regulatory Authority)

laboratorios liconsa, s.a. - tapentadol tartrate - prolonged-release tablet - tapentadol

Ireland - English - HPRA (Health Products Regulatory Authority)

laboratorios liconsa, s.a. - tapentadol tartrate - prolonged-release tablet - tapentadol

Ireland - English - HPRA (Health Products Regulatory Authority)

laboratorios liconsa, s.a. - tapentadol tartrate - prolonged-release tablet - tapentadol

Ireland - English - HPRA (Health Products Regulatory Authority)

laboratorios liconsa, s.a. - tapentadol tartrate - prolonged-release tablet - tapentadol

Ireland - English - HPRA (Health Products Regulatory Authority)

laboratorios liconsa, s.a. - tapentadol tartrate - prolonged-release tablet - tapentadol

Ireland - English - HPRA (Health Products Regulatory Authority)

laboratorios liconsa, s.a. - tapentadol tartrate - prolonged-release tablet - tapentadol

United States - English - NLM (National Library of Medicine)

actavis pharma, inc. - hydrocodone bitartrate (unii: no70w886kk) (hydrocodone - unii:6yks4y3wq7), acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d) - hydrocodone bitartrate 5 mg - hydrocodone bitartrate and acetaminophen tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses [see warnings ], reserve hydrocodone bitartrate and acetaminophen tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics): - have not been tolerated, or are not expected to be tolerated, - have not provided adequate analgesia, or are not expected to provide adequate analgesia hydrocodone bitartrate and acetaminophen tablets are contraindicated in patients with: - significant respiratory depression [see warnings ] - acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see warnings ] - known or suspected gastrointestinal obstruction, including paralytic ileus [see warnings ] - hypersensitivity to hydrocodone or acetaminophen

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - butorphanol tartrate (unii: 2l7i72ruhn) (butorphanol - unii:qv897jc36d) - butorphanol tartrate 10 mg in 1 ml - butorphanol tartrate nasal spray is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses (see warnings), reserve butorphanol tartrate nasal spray for use in patients for whom alternative treatment options (e.g., non-opioid analgesics) butorphanol tartrate nasal spray is contraindicated in: butorphanol tartrate nasal spray contains butorphanol, a schedule iv controlled substance. butorphanol tartrate nasal spray contains butorphanol, a substance with a high potential for abuse similar to other opioids including fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone, oxymorphone, and tapentadol. butorphanol tartrate nasal spray can be abused and is subject to misuse, addiction, and criminal diversion (see warnings). all patients treated with opioids require careful monitoring for signs of abuse and addiction, because use of

Canada - English - Health Canada

apotex inc - tapentadol (tapentadol hydrochloride) - tablet (immediate release) - 50mg - tapentadol (tapentadol hydrochloride) 50mg

Canada - English - Health Canada

apotex inc - tapentadol (tapentadol hydrochloride) - tablet (immediate release) - 75mg - tapentadol (tapentadol hydrochloride) 75mg